Cargando…

Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes

Single wall carbon nanotube (SWCNT) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] or desferrioxamine B [DFO]) and the tumor neovascular-targeting antibody E4G10. The E4G10 antibody specifically targeted the monomeric...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Alessandro, Villa, Carlos H, Holland, Jason P, Sprinkle, Shanna R, May, Chad, Lewis, Jason S, Scheinberg, David A, McDevitt, Michael R
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962274/
https://www.ncbi.nlm.nih.gov/pubmed/21042424
http://dx.doi.org/10.2147/IJN.S13300
_version_ 1782189180759048192
author Ruggiero, Alessandro
Villa, Carlos H
Holland, Jason P
Sprinkle, Shanna R
May, Chad
Lewis, Jason S
Scheinberg, David A
McDevitt, Michael R
author_facet Ruggiero, Alessandro
Villa, Carlos H
Holland, Jason P
Sprinkle, Shanna R
May, Chad
Lewis, Jason S
Scheinberg, David A
McDevitt, Michael R
author_sort Ruggiero, Alessandro
collection PubMed
description Single wall carbon nanotube (SWCNT) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] or desferrioxamine B [DFO]) and the tumor neovascular-targeting antibody E4G10. The E4G10 antibody specifically targeted the monomeric vascular endothelial-cadherin (VE-cad) epitope expressed in the tumor angiogenic vessels. The construct specific activity and blood compartment clearance kinetics were significantly improved relative to corresponding antibodyalone constructs. We performed targeted radioimmunotherapy with a SWCNT-([(225)Ac]DOTA) (E4G10) construct directed at the tumor vasculature in a murine xenograft model of human colon adenocarcinoma (LS174T). The specific construct reduced tumor volume and improved median survival relative to controls. We also performed positron emission tomographic (PET) radioimmunoimaging of the tumor vessels with a SWCNT-([(89)Zr]DFO)(E4G10) construct in the same murine LS174T xenograft model and compared the results to appropriate controls. Dynamic and longitudinal PET imaging of LS174T tumor-bearing mice demonstrated rapid blood clearance (<1 hour) and specific tumor accumulation of the specific construct. Incorporation of the SWCNT scaffold into the construct design permitted us to amplify the specific activity to improve the signal-to-noise ratio without detrimentally impacting the immunoreactivity of the targeting antibody moiety. Furthermore, we were able to exploit the SWCNT pharmacokinetic (PK) profile to favorably alter the blood clearance and provide an advantage for rapid imaging. Near-infrared three-dimensional fluorescent-mediated tomography was used to image the LS174T tumor model, collect antibody-alone PK data, and calculate the number of copies of VE-cad epitope per cell. All of these studies were performed as a single administration of construct and were found to be safe and well tolerated by the murine model. These data have implications that support further imaging and radiotherapy studies using a SWCNT-based platform and focusing on the tumor vessels as the target.
format Text
id pubmed-2962274
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29622742010-11-01 Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes Ruggiero, Alessandro Villa, Carlos H Holland, Jason P Sprinkle, Shanna R May, Chad Lewis, Jason S Scheinberg, David A McDevitt, Michael R Int J Nanomedicine Original Research Single wall carbon nanotube (SWCNT) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] or desferrioxamine B [DFO]) and the tumor neovascular-targeting antibody E4G10. The E4G10 antibody specifically targeted the monomeric vascular endothelial-cadherin (VE-cad) epitope expressed in the tumor angiogenic vessels. The construct specific activity and blood compartment clearance kinetics were significantly improved relative to corresponding antibodyalone constructs. We performed targeted radioimmunotherapy with a SWCNT-([(225)Ac]DOTA) (E4G10) construct directed at the tumor vasculature in a murine xenograft model of human colon adenocarcinoma (LS174T). The specific construct reduced tumor volume and improved median survival relative to controls. We also performed positron emission tomographic (PET) radioimmunoimaging of the tumor vessels with a SWCNT-([(89)Zr]DFO)(E4G10) construct in the same murine LS174T xenograft model and compared the results to appropriate controls. Dynamic and longitudinal PET imaging of LS174T tumor-bearing mice demonstrated rapid blood clearance (<1 hour) and specific tumor accumulation of the specific construct. Incorporation of the SWCNT scaffold into the construct design permitted us to amplify the specific activity to improve the signal-to-noise ratio without detrimentally impacting the immunoreactivity of the targeting antibody moiety. Furthermore, we were able to exploit the SWCNT pharmacokinetic (PK) profile to favorably alter the blood clearance and provide an advantage for rapid imaging. Near-infrared three-dimensional fluorescent-mediated tomography was used to image the LS174T tumor model, collect antibody-alone PK data, and calculate the number of copies of VE-cad epitope per cell. All of these studies were performed as a single administration of construct and were found to be safe and well tolerated by the murine model. These data have implications that support further imaging and radiotherapy studies using a SWCNT-based platform and focusing on the tumor vessels as the target. Dove Medical Press 2010-10-05 2010 /pmc/articles/PMC2962274/ /pubmed/21042424 http://dx.doi.org/10.2147/IJN.S13300 Text en © 2010 Ruggiero et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Ruggiero, Alessandro
Villa, Carlos H
Holland, Jason P
Sprinkle, Shanna R
May, Chad
Lewis, Jason S
Scheinberg, David A
McDevitt, Michael R
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
title Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
title_full Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
title_fullStr Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
title_full_unstemmed Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
title_short Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
title_sort imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962274/
https://www.ncbi.nlm.nih.gov/pubmed/21042424
http://dx.doi.org/10.2147/IJN.S13300
work_keys_str_mv AT ruggieroalessandro imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes
AT villacarlosh imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes
AT hollandjasonp imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes
AT sprinkleshannar imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes
AT maychad imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes
AT lewisjasons imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes
AT scheinbergdavida imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes
AT mcdevittmichaelr imagingandtreatingtumorvasculaturewithtargetedradiolabeledcarbonnanotubes